BioSpace News Archive

Gemina Laboratories Ltd. is pleased to provide the following strategic overview and share an outlook for 2022 and beyond.

Xerostomia is a condition resulting in dry mouth caused by the minimal amount or absence of saliva in the mouth. Xerostomia is not contemplated to be a disease, but is considered a symptom.

Shouse Brings More Than 15 Years of Analytics Technology Experience to BioCare, Inc. During a Time of Rapid Growth.

Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

Bruno Villetelle, Global Head of Data and Digital in Novartis Global Drug Development, joins Seqster as they prepare for unprecedented growth and expansion.

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that NASDAQ has halted trading of the Company’s common stock.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces progress with expanding manufacturing capacity of its portfolio of Quality Assessment Products and its “DxTM™” brand viral transport medium – via renovating and equipping its second and third manufacturing sites in Mississauga, ON.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022 before the opening of the U.S. financial markets.

LianBio (Nasdaq: LIAN), today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation in China for mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM).

Evogene Ltd. announces today that it will release its financial results for the full year and fourth quarter of 2021 on Thursday, March 10, 2022 .